anti-Bmf (mouse/rat) mAb (17A9)
| Code | Size | Price |
|---|
| AG-20T-0131-C100 | 100 ug | £300.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species:
- Mouse
- Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Bcl-2-modifying Factor
Concentration:
1mg/ml
EClass:
32160000
Endotoxin:
<0.1EU/µg purified protein (LAL test; Lonza).
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 0.02% sodium azide.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant full length mouse Bmf and synthetic peptides corresponding to aa 13-27 and aa 112-126 of mouse Bmf.
Long Description:
Monoclonal Antibody. Recognizes an epitope within the peptide sequence aa 13-27 of mouse and rat Bmf. Detects bands of ~25kDa and ~30kDa by Western blot, corresponding to endogenous Bmf and BmfL. Does not cross-react with human Bmf. Isotype: Rat IgG2akappa. Clone: 17A9. Applications: ELISA, FACS, ICC, IHC, IP, WB. Liquid. In PBS containing 0.02% sodium azide. Bmf (Bcl-2-modifying factor) belongs to the Bcl-2 protein family. Bcl-2 family members form hetero- or homo-dimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. Bmf contains a single Bcl-2 homology domain 3 (BH3), and has been shown to interact with other Bcl-2 proteins and functions as an apoptotic activator. Two different start sites can give rise to two proteins of 25 or 30 kDa. It is found to be sequestered to myosin V motors by its association with dynein light chain 2 (DLC2), which may be important for sensing intracellular damage and triggering apoptosis.
NCBI, Uniprot Number:
Q91ZE9
Package Type:
Plastic Vial
Product Description:
Bmf (Bcl-2-modifying factor) belongs to the Bcl-2 protein family. Bcl-2 family members form hetero- or homo-dimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. Bmf contains a single Bcl-2 homology domain 3 (BH3), and has been shown to interact with other Bcl-2 proteins and functions as an apoptotic activator. Two different start sites can give rise to two proteins of 25 or 30 kDa. It is found to be sequestered to myosin V motors by its association with dynein light chain 2 (DLC2), which may be important for sensing intracellular damage and triggering apoptosis.
Purity:
>95% (SDS-PAGE)
Specificity:
Recognizes an epitope within the peptide sequence aa 13-27 of mouse and rat Bmf. Detects bands of ~25kDa and ~30kDa by Western blot, corresponding to endogenous Bmf and BmfL. Does not cross-react with human Bmf.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia: J. Kuroda, et al.; Cell Death Differ. 14, 1667 (2007) | Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiation-induced thymic lymphoma development: V. Labi, et al.; J. Exp. Med. 205, 641 (2008) | Suppression of B cell lymphomagenesis by the BH3-only proteins Bmf and Bad: A. Frenzel, et al.; Blood 115, 995 (2010) | BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis: F. Grespi, et al.; Cell Death Diff. 17, 1672 (2010)